Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Etienne Muller

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

E. Muller, M. Olivi, M. Coudé, B. Roquebert

Author affiliations

  • Cerba HealthCare, 35000 - Saint-Ouen-L'aumône/FR

Resources

This content is available to ESMO members and event participants.

Abstract 117P

Background

PARP inhibitors are now the standard of care for patients with ovarian cancer. The determination of HRD status has become essential to predict sensitivity to these targeted therapies, and has to be integrated in routine oncology assays, beyond the search for BRCA1/2 pathogenic variants. We present the integration of an HRD assay based on tumor shallow whole genome sequencing (sWGS) fully integrated in an existing NGS workflow dedicated to somatic oncology.

Methods

25 samples from ovarian cancer with HRD status was determined using two CE-IVD assays (5 Sofia Genetics / 20 Myriad Genetics). Samples have been re-analysed, starting from FFPE blocks. We performed new DNA extractions from FFPE blocks followed by our dedicated workflow for solid tumor using NGS sequencing. DNA samples were prepared using hybridation method (Twist BioScience®) with Unique Molecular Identifiers (UMI). Part of libraries from HRD samples were collected before the capture step, and directly pooled for sequencing on Illumina® NextSeq 500. sWGS produced were analysed by a dedicated CE-IVD Bioinformatic pipeline for HRD status determination (SeqOne®).

Results

3 different runs of 10 samples each have been sequenced for replicability evaluation. No failure were encountered on any of the sequenced samples. The mean depth, Q30 quality and duplicate rates for sWGS produced were respectively 1.12X / 88.8% / 1.94%, far above the minimum requirements for analysis (> 0.1X). Replicability analysis show an average variation of 4% of the final HRD score. Regarding the HRD status determination, our results show an agreement of 93.3% with the status previously determined, in line with the results obtained by SeqOne during the validation of their bioinformatic analysis (93%).

Conclusions

Theses results demonstrate innovative integration into routine genetics’s laboratory. This implemented methodology allows us to provide a full report with both BRCA1/BRCA2 variant identification and the HRD status for each patient, in an efficient and cost-effective workflow.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.